The Respimat® success story: Boehringer Ingelheim doubles its production capacity

Boehringer IngelheimSuccessful treatment of respiratory diseases also depends on how much of the active substance enters the patient's lung. Boehringer Ingelheim's Respimat® Soft Inhaler and its long-lasting aerosol cloud effectively transport the active substance into the lung. As a result of increasing demand for this innovative inhalation system, the research-driven pharmaceutical company Boehringer Ingelheim is investing approximately EUR 85 million in its Dortmund facility to double the Respimat® production to 44 million inhalers annually by 2015. This expansion will also create more than 100 new jobs in Dortmund at full capacity utilisation.

"We expect that the Respimat® business will continue its strong growth. For this reason, Boehringer Ingelheim is now laying the symbolic foundation stone to expand production capacity for the Respimat® Soft Inhaler at the Dortmund facility. In future, we will continue to meet the increasing demand, while at the same time fulfilling our claim to provide patients with innovative medications," stated Professor Wolfram Carius, member of Boehringer Ingelheim's Board of Managing Directors in charge of Biopharmaceuticals and Operations.

"Doubling our Respimat® production capacity will allow us to produce up to 44 million inhalers annually in the future. The success story of Respimat® continues." The Respimat® Soft Inhaler is produced in Dortmund by subsidiary Boehringer Ingelheim microParts GmbH. Part of the Boehringer Ingelheim group since 2004, it manufactures products for global distribution of the pharmaceutical company.

"North Rhine-Westphalia is Germany's industrial hub - and by investing millions here in Dortmund, Boehringer Ingelheim is underscoring the importance of our state to industry," emphasised Garrelt Duin, Minister of Economic Affairs, Energy, Industry, SMEs and Trade for the State of North Rhine-Westphalia at the start of production capacity expansion in Dortmund. "To develop such high technology, a long-term effort is required before the whole thing really pays off," said Duin. "North Rhine-Westphalia and the City of Dortmund are very fortunate that as a family-owned company, Boehringer Ingelheim has the necessary stamina."

More than 450 employees are currently employed for the manufacture of Respimat® Soft Inhalers in Dortmund at Boehringer Ingelheim microParts GmbH. Respimat® is filled with its active pharmaceutical substances at the company's headquarters in Ingelheim, from where it is distributed around the world.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...